Provides relative to the Medicaid Pharmaceutical and Therapeutics Committee

House Bill 927 amends the statute governing the Medicaid Pharmaceutical and Therapeutics Committee by making three substantive changes to R.S. 46:153.3. First, the bill removes language from the section title that references peer-based prescribing and dispensing practice patterns. Second, the bill expands the committee's composition by adding one physician or pharmacist from each Medicaid managed care organization as a new member category, adding to the existing fifteen members appointed by the governor. Third, the bill repeals the restriction that had prohibited the Louisiana Department of Health from using prior authorization to limit anti-retroviral prescription drugs that are determined to be medically necessary for the treatment and prevention of HIV/AIDS.

The practical effect of these changes impacts multiple stakeholders in Louisiana's Medicaid system. Medicaid managed care organizations will gain direct representation on the committee through the addition of physician and pharmacist members, potentially allowing these organizations greater influence in drug formulary decisions. Patients with HIV/AIDS will face new restrictions on access to anti-retroviral medications, as the Department of Health is no longer statutorily prohibited from requiring prior authorization for these drugs. The expanded committee membership may alter decision-making dynamics regarding which pharmaceutical therapies are covered and under what conditions.

These changes operate within the existing framework of R.S. 46:153.3, which establishes the Medicaid Pharmaceutical and Therapeutics Committee as a regulatory body with authority over drug formulary restrictions and prior authorization requirements for Medicaid beneficiaries. The committee's composition and authority directly affect Louisiana's Medicaid program administration under Title XIX of the federal Social Security Act. The repeal of the prior authorization restriction on anti-retroviral drugs removes a specific statutory protection that had been in place, allowing the state greater discretion in managing costs and access to HIV/AIDS medications within its Medicaid program.